SURVEY ON THE USE OF CEFTAZIDIME-AVIBACTAM AND CEFIDEROCOL IN EUROPEAN NICUs

Dear Colleague,

A team of neonatal pharmacology researchers has created a survey on new antibiotics, specifically ceftazidime/avibactam and cefiderocol. Neonatal sepsis is a major contributor to infant mortality, with approximately 1.3 million cases and 230,000 deaths annually. Multidrug-resistant (MDR) bacteria are increasingly recognized as causes of both early-onset (EOS) and late-onset sepsis (LOS) in Neonatal Intensive Care Units (NICUs), where Gram-negative pathogens account for 39–64% of cases.

Ceftazidime/avibactam, a cephalosporin/beta-lactamase inhibitor, is approved for patients 3 months and older to treat complex Gram-negative infections. Cefiderocol, effective against carbapenemase-producing bacteria, has been successfully used in preterm neonates for LOS. The rising incidence of MDR infections in European NICUs highlights the need for data on these new antimicrobials.

This survey aims to evaluate ceftazidime/avibactam and cefiderocol use in European NICUs.

We invite NICU directors or senior neonatologists to participate.

The survey will take about 15 minutes, and all responses will be anonymized.

For questions, please get in touch with us at the provided email addresses.

Nunzia Decembrino: n.decembrino@policlinico.unict.it;

Roberta Leonardi: leonardi.roberta@outlook.it;

Mario Giuffrè: mario.giuffre@unipa.it;

Anne Smits: anne.smits@uzleuven.be;

Karel Allegaert: karel.allegaert@uzleuven.be;

Cristina Arribas: carribass@unav.es;

Carlo Pietrasanta: carlo.pietrasanta@unimi.it;

Genny Raffaeli: genny.raffaeli@gmail.com;

Andrea Ronchi: andrea.ronchi@policlinico.mi.it;

Luana Conte: luana.conte@unipa.it;

Monica Riaza: mriazagomez@unav.es;

Roberto Ortiz: rortizmovilla@gmail.com;

Felipe Garrido: fgarridom@unav.es;

Giacomo Cavallaro: giacomo.cavallaro@policlinico.mi.it.

Thank you for considering this important research.